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1. Introduction 
Toxicokinetics (TK) refers to the kinetics of absorption, distribution, metabolism, and 
elimination (ADME) processes where both first and zero order kinetics are expected and 
these processes can vary over a wide range of doses. The goal of TK and pharmacokinetic 
studies are similar, which is to define the ADME properties of a drug candidate (Dixit & 
Ward, 2007). Therefore, the wide range of studies to define these ADME properties (e.g., in 
vitro and in vivo metabolism, animal mass balance, and distribution studies) performed in 
the pharmacokinetic evaluation of the drug candidate can also serve to help guide the 
toxicokinetic evaluation of the same drug candidate with the knowledge that first and zero 
order kinetics might be expected in the ADME processes at the higher doses of this drug 
candidate in the safety studies. 
Now it is widely accepted that toxic effects can be better extrapolated from animals to 
humans when these comparisons are based on TK instead of dose alone. For example, the 
safety margin that is based on the ratio of the animal exposure at no observed adverse 
effect level (NOAEL) to human exposure at the efficacious dose is a key predictor of 
human safety risk. To calculate this safety margin, the animal and human exposure is 
determined by analyzing drug and metabolites concentrations in plasma, which is the 
most practical and widely accepted way of assessing this risk (Dixit & Ward, 2007). 
However, most safety issues are not observed in the plasma but in the organs and/or 
tissues. Therefore, is sampling plasma a good measure of the safety margin for the risk 
assessment of safety?   
Sampling plasma and extrapolating this exposure to organs or tissues assumes that 1) 
concentration of drug in plasma is in equilibrium with concentrations in tissues, 2) changes 
in plasma drug concentrations reflect changes in tissue drug concentrations over time, and 
3) distribution of drug and its metabolites is not affected by polarized cells (e.g., drug 
transporters and enzymes) that protect a lot of these tissues. Drug transport into tissues may 
not be a passive process and may depend on drug transporters (Ward, 2008), thus these 
assumptions may result in an inaccurate assessment of target organ exposure to drug and 
metabolites. Even without a drug candidate being a substrate for a drug transporter, 
lysosomal trapping of weak bases (e.g., liver and lung) or accumulation in membranes (e.g., 
muscle) can occur that can give rise to preferential distribution of the drug and its 
metabolites (MacIntyre & Cutler, 1988). Therefore, plasma is sometimes not a good 
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surrogate for tissue levels of drug and its metabolites, especially for the assessment of risk 
for some types of organ-specific toxicity.  
The following case examples will illustrate how focusing on drug and metabolites in these 
tissues (where toxicity is observed) instead of plasma increases understanding of the nature 
of the toxicity and in some cases allows the efficient identification of a backup drug that has 
markedly less potential to cause that specific organ toxicity under investigation. These case 
examples are categorized by the different organs where toxicity was investigated and are 
generated from the author’s personal experience in the pharmaceutical industry. 
2. Case example: Toxicokinetics and testicular toxicity 
This case example (described below) will highlight 1) preferential distribution of parent and 
metabolites to tissue, 2) a predominant metabolite that is different in the tissue versus 
plasma, and 3) accumulation of parent and metabolite that occurs in tissue and not in 
plasma. Furthermore, the case example will highlight that focusing on tissue burden of the 
drug and its metabolites (and not plasma concentrations) may actually ensure that a backup 
does not produce the same toxicity. 
2.1 Testicular toxicity in rat 
In a 13-week rat safety study, testicular atrophy was observed in rats at all doses tested (10, 
50, and 250 mg/kg/day); however, these findings were not observed in the 2-week study. 
At the dose of 250 mg/kg/day, testicular atrophy was observed in approximately 50% of all 
rats. At doses of 10 and 50 mg/kg/day, these findings were observed in only 10% of rats but 
responsibility of Drug A for this toxicity could not be discounted (i.e., unequivocal). 
Therefore, no NOAEL could be assigned in this study, which markedly complicated the 
further development of this drug candidate. 
2.2 Role of toxicokinetics in rat testicular toxicity 
From the rat quantitative whole body autoradiography (QWBA) study, preferential 
distribution of Drug A-derived radioactivity to the testes was observed; furthermore, this 
radioactivity was retained in the testes markedly longer compared to other tissues (Figure 
1). Since distribution of radioactivity included both parent and its metabolites and the dose 
in the rat QWBA study was based on the lowest dose of the rat safety study (i.e., 10 
mg/kg/day), a cold study was initiated where rats were dosed with a single oral dose of 
Drug A at 50 mg/kg (similar to the mid dose in the rat safety study). After this single oral 
dose, the plasma, testes, and epididymes of the rats were collected at different time points 
and analyzed for Drug A and its two known metabolites (M1 and M2). Interestingly, the 
predominant metabolite in plasma (i.e., M2) was not the predominant metabolite in testes. 
M1 preferentially distributed to the testes from plasma; whereas, M2 had limited 
distribution to this tissue (Table 1 and 2). Furthermore, the Tmax of M1 was 48 hours in testes 
suggesting a large accumulation potential of this metabolite in testes compared to plasma. 
Indeed after a follow-up study for six months of repeated daily oral dosing, M1 
accumulated approximately five-fold in the testes; whereas, the parent did not accumulate 
(Figure 2). Furthermore, parent and M1 did not accumulate in the plasma during the 6-
month rat safety study (data not shown). 
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Fig. 1. Total Radioactivity (TR) Concentrations versus Time Profile of Drug A-derived 
Radioactivity in Rat Plasma, Testicle, Liver, and Lung. 
Long Evans rats were dosed with a single oral dose of 10 mg/kg [14C]-labeled Drug A. At 
different times after this dose, rats were sacrificed via exsanguination (cardiac puncture) 
under isoflurane anesthesia and blood (approximately 2 to 10 mL) was collected into tubes 
containing K2EDTA immediately prior to collection of carcasses for QWBA. Samples were 
maintained on wet ice and refrigerated until aliquoted and centrifuged to obtain plasma. 
Immediately after blood collection the animals were prepared for QWBA. The carcasses 
were immediately frozen in a hexane/dry ice bath for approximately 8 minutes. Each 
carcass was drained, blotted dry, placed into an appropriately labelled bag, and placed on 
dry ice or stored at approximately -70°C for at least 2 hours. Each carcass was then stored at 
approximately -20°C. The frozen carcasses were embedded in chilled 
carboxymethylcellulose and frozen into blocks. Embedded carcasses were stored at 
approximately -20°C in preparation for autoradiographic analysis. 
 
  
Half Life
(hr) 
Tmax
(hr)
Cmax 
(ng/mL or g) 
AUClast 
(ng*hr/mL or g) 
AUCinf 
(ng*hr/mL or g) 
Plasma M1 4 4 29 401 410 
Plasma M2 6 4 1033 11983 12025 
Plasma Parent 5 4 3712 43454 43491 
Testes M1 46 48 1182 156763 158157 
Testes M2 7 4 76 412 947 
Testes Parent 54 8 9061 684074 692652 
Epididymes M1 9 8 1441 25949 26064 
Epididymes M2 7 4 231 1215 2908 
Epididymes Parent 51 8 6676 115682 116647 
Table 1. Toxicokinetic Profile of Drug A and its Metabolites in Rat Plasma, Testes, and 
Epididymes. 
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Fed Sprague Dawley rats (n=27) were administered a single oral dose of 50 mg/kg Drug A. 
Testes, epididymes, and plasma were collected at 1, 4, 8, 24, 48, 72, 96, 168, and 336 hours 
post dose from three rats at each time point. Bioanalysis of plasma, testes, and epididymes 
for Drug A (Parent) and its metabolites M1 and M2 was performed. Toxicokinetic 
parameters were determined on plasma, testes, and epididymes.  
 
  Cmax AUClast AUCinf 
Testes M1 40 391 386 
Testes M2 0.07 0.03 0.08 
Testes Parent 2 16 16 
Epididymes M1 49 65 64 
Epididymes M2 0.22 0.10 0.24 
Epididymes Parent 2 3 3 
Table 2. Tissue to Plasma Ratios of Drug A and its metabolites in Rat Plasma, Testes, and 
Epididymes. 
See description of Table 1 for experimental details. After toxicokinetic parameters were 
determined on testes, epididymes, and plasma, tissue to plasma ratios were calculated.  
 
 
Fig. 2. Distribution of Drug A and its Metabolite, M1, in the Rat Testes after 6 Months of 
Repeated Daily Dosing (50 mg/kg/day) Compared to a Single Oral Dose (50 mg/kg) 
Fed Sprague Dawley rats (n=4) were administered a single oral dose or repeated daily oral 
doses of 50 mg/kg/day Drug A for 6 months. Testes were collected at 24 hours post dose. 
Bioanalysis of testes for Drug A (Parent) and M1 was performed. Concentrations of Drug A 
and M1 after 6 months of repeated daily oral dosing (50 mg/kg/day) were compared to a 
single oral dose (50 mg/kg) at 24 hours post dose (see description of Table 1 for 
experimental details of the single oral dose study).  
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2.3 Identification of a backup molecule with limited potential for testicular toxicity 
In order to identify a backup to this molecule (e.g., Drug A), screening potential backups in 
terms of their toxicity potential to rat testicular atrophy was not practical because of the time 
required for the toxicity to be observed (i.e., more than 2 weeks). Therefore, another method 
of screening potential backups needed to be initiated.  
To aid the identification of this backup, the rat QWBA study of a prior drug candidate for 
this target (referred to as Drug B) was assessed where Drug B did not induce testes toxicity 
in rat during long-term safety studies. Interestingly, Drug B-derived radioactivity was 
approximately equivalent in blood and testes (Table 3), suggesting that the reduced burden 
of this tissue may have markedly lowered the susceptibility for this toxicity compared to the 
structurally similar molecule, Drug A. This markedly lowered distribution to the testes was 
also mirrored in the volume of distribution calculated after an single intravenous 
administration of Drug A and B, where the volume of distribution was markedly lower for 
Drug B compared to Drug A in every animal species tested (e.g., rat, dog, and monkey). 
Therefore to select future backups of Drug A into development, the volume of distribution 
was calculated from similar studies with administration of potential backup drug 
candidates via the intravenous route. These studies led to the identification of a potential 
drug candidate with similar distribution properties of Drug B (i.e, lower volume of 
distribution in every animal species tested after a single intravenous dose compared to Drug 
A). This potential backup to Drug A (referred to as Drug C) was then assessed in a rat 
QWBA study. In this study, Drug C-derived radioactivity was approximately equivalent in 
blood and testes (Table 4). From these encouraging results, Drug C was advanced into 
further development where no testicular toxicity has been observed in long-term rat safety 
studies. These results support the hypothesis that reduced tissue burden of the drug and its 
metabolites may actually predict that a backup does not produce the same toxicity. 
 
Time 
(hr) 
0.5 2 4 8 12 24 48 72 120 
Blood 21.0 17.0 15.5 8.22 3.09 0.153 ND ND ND 
Testis 2.84 7.54 15.4 9.98 5.26 0.346 0.135 BLQ BLQ 
Table 3. Tissue Concentrations (µg equivalents/g) of Drug B-derived Radioactivity in Rat 
Plasma and Testis. 
Long Evans rats were dosed with single oral dose of 30 mg/kg [14C]-labeled Drug B. See 
description of Figure 1 for experimental details.  
 
Time (hr) 1 4 8 24 72 168 336 
Blood 4530 1280 310 58.3 BLQ ND ND 
Testis 2240 989 456 105 BLQ BLQ BLQ 
Table 4. Tissue Concentrations (µg equivalents/g) of Drug C-derived Radioactivity in Rat 
Plasma and Testis. 
Long Evans rats were dosed with a single oral dose of 10 mg/kg [14C]-labeled Drug C. See 
description of Figure 1 for experimental details.  
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2.4 Conclusion 
Knowledge of tissue toxicokinetics will increase the understanding about the potential 
mechanism of an organ-specific toxicity and can potentially assist in identifying a backup 
drug candidate that has a markedly lower potential for this organ-specific toxicity.  
3. Case example: Toxicokinetics and liver toxicity 
This case example (described below) will highlight an investigation into liver toxicity where 
the mechanism of the liver toxicity was questioned. This drug candidate induced a strong 
pharmacological response; therefore, an investigation was launched to investigate whether 
the liver toxicity induced by this drug was a result of its strong pharmacology or an off 
target effect (i.e., independent of its targeted receptor pharmacology) from one of the 
metabolites of the drug.  
3.1 Liver toxicity in dog 
In a dog toleration study at the lowest dose tested (10 mg/kg), slight, acute central-lobular 
and portal inflammation with individual hepatocyte necrosis was observed. Therefore, no 
NOAEL could be assigned in this study which markedly complicated the further 
development of this drug candidate. 
3.2 Role of toxicokinetics in dog liver toxicity 
Even though this drug candidate was known to elicit a strong pharmacological response that 
could be capable of inducing the adverse effect observed in the dog toleration study, the 
potential of this drug candidate to form an acyl glucuronide (M2) in liver was evident and thus 
this metabolite may also be the cause of these adverse effects (Kenny et al., 2005). Furthermore, 
the potential preferential distribution of this drug candidate to the liver may also predispose 
its adverse effects. Therefore to investigate these hypotheses, the plasma and liver (also kidney 
and fat for comparison) were analyzed for drug candidate and its metabolites in the dog after 
14 days of repeated daily oral doses of the drug candidate (i.e., parent). 
After toxicokinetic evaluation of the tissues and plasma, the concentrations of parent in liver 
were consistently lower than plasma at 2, 6, and 24 hours postdose, suggesting no 
preferential distribution of the drug to the liver (Table 5). Furthermore, the acyl glucuronide 
metabolite (M2) along with other metabolites (M1, M3, and M4) were only observed in the 
plasma and not in the liver (Table 6), suggesting that these metabolites were not the cause of 
the observed liver toxicity. These results suggested that the observed liver toxicity in dog 
was caused by the strong pharmacological response of the drug candidate and probably not 
caused by an off target effect of M2 (or any other metabolites observed in plasma). 
Furthermore, the lack of preferential distribution of parent to the liver indicated that the 
toxicokinetic analysis of plasma exposure was correct in evaluating the risk for observed 
liver toxicity in the potential further development of this drug candidate.  
3.3 Conclusion 
Toxicokinetic evaluation of tissue (where toxicity is observed) and plasma for drug and its 
metabolites will allow further mechanistic understanding of the cause of the observed tissue 
toxicity and will aid in the choice of the most relevant matrix for sampling in order for the 
correct evaluation of risk in further development of the drug candidate.  
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  Concentration (µg/mL or g)  
Day Time 
(hr) 
Plasma Plasma + 
Acid 
Liver Liver + 
Acid 
Kidney Kidney + 
Acid 
Fat  
Day 1 2 292 373 130 168 209 180 59 Mean 
  35 114 17 24 46 68 11 SD 
 6 286 284 131 96 181 123 65 Mean 
  112 92 35 12 102 57 4 SD 
 24 54 48 46 28 68 34 61 Mean 
  44 37 24 16 37 25 5 SD 
Day 14 2 295 381 226 140 245 90 73 Mean 
  141 208 100 27 160 38 12 SD 
 6 293 275 284 128 187 94 71 Mean 
  89 110 72 29 27 35 5 SD 
 24 39 37 41 29 52 36 72 Mean 
  54 53 40 24 61 43 3 SD 
Table 5. Concentration-Time Profile of Parent in Dog Plasma, Liver, Kidney, and Fat. 
Fed Beagle dogs (n=18) were administered a single oral dose or repeated daily oral doses for 
14 days of 10 mg/kg drug. Liver, kidney, fat, and plasma were collected at 2, 6, and 24 hours 
post dose from three dogs at each time point with and without formic acid (formic acid was 
added to potentially increase the stability of the acyl glucuronide metabolite). Bioanalysis of 
liver, kidney, fat, and plasma for drug candidate was performed.  
 
Plasma Plasma + Acid Liver Liver + Acid 
Metabolite Type Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 Day 1 Day 14 
Parent - 116,860,326 123,174,663122,389,879122,716,07227,431,25236,110,99528,993,390 29,924,921 
M1 
Oxidation + 
Sulfation 
ND ND ND ND ND ND ND ND 
M2 Glucuronidation 5,299,597 3,790,520 3,552,836 2,817,400 ND ND ND ND 
M3 Oxidation ND ND ND ND ND ND ND ND 
M4 Oxidation 453,680 1,035,337 553,582 1,045,264 ND ND ND ND 
ND = not detected 
Table 6. Peak Area Counts Versus Time Profile of Parent and its Metabolites in Dog Plasma, 
Liver, Kidney, and Fat. 
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Fed Beagle dogs (n=18) were administered a single oral dose or repeated daily oral doses for 
14 days of 10 mg/kg drug. Liver, kidney, fat, and plasma were collected at 24 hours post 
dose from three dogs at each time point with and without formic acid (formic acid was 
added to potentially increase the stability of the acyl glucuronide metabolite). Bioanalysis of 
liver, kidney, fat, and plasma for drug (Parent) and it metabolites (M1, M2, M3, and M4) was 
performed. Peak areas were integrated for both parent and metabolites in each matrix. Data 
from kidney and fat are not shown.   
4. Case example: Toxicokinetics and central nervous system (CNS) toxicity 
This case example (described below) will highlight an investigation into CNS toxicity where 
the lead drug candidate displayed CNS toxicity in the monkey and a backup molecule 
needed to be identified. This example highlights utilization of the efflux transporter, P-
glycoprotein (Pgp), to limit the tissue distribution of the backup drug candidate to the CNS 
in order to limit CNS toxicity potential.  
4.1 CNS toxicity in monkey 
In a Cynomolgus monkey toleration study at the 100 mg/kg/day dose (repeat daily oral 
dosing), test article-related clinical signs observed in the male monkey were characterized 
by vomiting, ptosis, decreased activity, prostration, tremors, convulsion and ataxia. A slight 
safety margin was identified (approximately 7-fold); however, this margin was not large 
enough to confidently advance this drug candidate into longer GLP safety studies in 
monkey.  
4.2 Role of toxicokinetics in monkey CNS toxicity 
Unfortunately, the brains of these monkeys were not sampled after the monkey toleration 
study. However, plasma and brain exposures in the mouse were known for this drug 
candidate. Mice express similar membrane proteins (e.g., Pgp and BCRP) in their blood 
brain barrier compared to Cynomolgus monkeys (Ito et al., 2011); therefore, we 
hypothesized that brain penetration of this drug candidate in mouse may approximate the 
respective brain penetration in monkey.  
The brain to plasma ratio of this drug candidate was large (i.e., 22) in mouse; furthermore, 
drug was retained in the mouse brain compared to plasma (Figure 3). These results 
suggested that the drug candidate was preferentially distributed to the brain with a large 
accumulation potential. This large accumulation potential suggested that the safety margin 
(established in the monkey toleration study) might decrease with the increased duration of 
the safety studies, further compromising the developability of this lead candidate.  
4.3 Identification of a backup molecule with limited potential for CNS toxicity 
In order to identify a backup molecule with limited potential for the observed CNS toxicity 
of the lead drug candidate, screening potential backup molecules for CNS toxicity in 
monkey would be resource intensive. Furthermore from an animal usage and management 
perspective, reduction of potential primate mortality was optimal. Since toxicological 
screening for a potential backup was unfavorable, reduction in the distribution of a backup 
to the CNS was a possible solution. Marked structural alterations of the physiochemical 
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properties for this chemical series to alter CNS distribution were not possible since these 
alterations markedly reduced potency for the pharmacological receptor. Interestingly, some 
of these molecules (in the same chemical series) were identified as substrates for Pgp. In the 
MDR1-MDCK cell model, the efflux ratio of the Pgp substrates was between 2 and 3. Since 
Pgp is known to reduce CNS distribution through efflux of drug candidate from the apical 
membrane of the endothelial cells in the blood brain barrier into the blood (Cordon-Cardo et 
al., 1989), the effect of Pgp on the CNS distribution of these potential backup molecules was 
determined in the mouse (as discussed previously, monkeys were not  a practical model for 
this exploration). CNS concentrations were approximately 10-fold less for one of these 
backup drug candidates compared to the lead drug candidate (Figure 4). Therefore, this 
backup drug candidate was advanced into clinical trials and CNS toxicity was never 
observed in monkey and human. 
 
 
 
 
 
 
 
Fig. 3. Concentration-Time Profile of Lead Drug Candidate in Mouse Brain and Plasma after 
a Single Oral Dose (20 mg/kg) 
Fasted CD1 mice (n=27) were administered a single oral dose (20 mg/kg) of the lead drug 
candidate. Brains and plasma were collected at 0.25, 0.5, 1, 2, 4, 6, 8, 24, and 48 hours post 
dose from three mice at each time point. Bioanalysis of brain and plasma of the lead drug 
candidate was performed. 
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Fig. 4. Dose Normalized CNS Concentration-Time Profile of Drug Candidate in Mouse Brain 
and Plasma after a Single Oral Dose (20 mg/kg for lead and 5 mg/kg for backup) 
Fasted CD1 mice (n=54) were administered a single oral dose of 20 mg/kg of the lead or 5 
mg/kg of the backup drug candidate. For the lead drug candidate, brains were collected at 
0.25, 0.5, 1, 2, 4, 6, 8, 24, and 48 hours post dose from three mice at each time point. For the 
backup drug candidate, brains were collected at 0.5, 1, 4, 6, 24, and 48 hours post dose from 
three mice at each time point. Bioanalysis of brains for the lead and backup drug candidate 
was performed.  
4.4 Conclusion 
Development of a backup drug candidate that is a substrate for efflux transporters which 
limit its distribution to the CNS (e.g., Pgp) can reduce the potential for this backup to cause 
CNS toxicity where the prior lead drug candidate demonstrated this toxicity in animal 
safety studies.  
5. Future use of safety margins in tissues 
In the future, more thorough risk assessment of safety will include safety margins from 
exposure of drug and its metabolites in the tissues (in addition to plasma) where organ 
specific toxicity is observed. The challenge in this endeavor is the assessment of drug 
exposure in human tissues since these tissues cannot be easily sampled from most human 
volunteers. Therefore, creative sampling methods must be applied. For example, 
noninvasive in vivo measurements such as sampling excreta (urine, feces, bile, and semen) 
will be useful. Furthermore, in vitro systems such as the hepatocyte sandwich-culture model 
(Chandra & Brouwer, 2004), and humanized mice (Jiang et al., 2011), combined with 
physiologically based pharmacokinetic (PBPK) modelling (Kusuhara & Sugiyama, 2010) can 
also replace the need for direct sampling of human tissues.  
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5.1 Sampling excreta to estimate drug and metabolites in tissues 
The concept of sampling excreta to estimate drug and metabolites in human tissues is still 
evolving. The importance of understanding absolute abundance of metabolites from 
sampling excreta was highlighted by the need to understand the importance of metabolites 
in safety testing or MIST (Baillie et al., 2002; Smith & Obach, 2005). Smith and Obach 
concluded that the risk assessment of metabolites would seem more prudent if it was based 
on absolute mass and not proportion of drug-related material (Smith & Obach, 2005); 
therefore, sampling excreta and analyzing total amount of metabolite excreted would be 
more useful than sampling plasma (especially at higher dose of the drug). The 
recommendation for sampling excreta was based on determining the entire body burden of 
the metabolites for this MIST guidance and less about sampling excreta to estimate drug and 
metabolites in tissues.  
In animals, the concept of sampling excreta to estimate drug and metabolites in tissues has 
been applied in a limited fashion. For example in beef steers treated with gentamicin, a 
small residue remains bound to the kidney cortex tissue for many months (this residue is 
unacceptable at the time of slaughter). Interestingly, plasma levels of gentamicin declined 
rapidly to no detectable levels within 3 days after intramuscular administration of 
gentamicin, while measurable amounts in urine persisted for 75 days before the 
concentration of gentamicin declined to levels too low to quantitate by the available liquid 
chromatography tandem mass spectrometry (LC/MS/MS) technique (Chiesa et al., 2006). 
An estimated correlation between an extrapolation of urine gentamicin concentration to the 
corresponding kidney tissue sample suggested a urine to kidney tissue relationship of 1:100. 
A test system sufficiently sensitive to a urine gentamicin concentration of 1 ng/mL 
correlated with the estimated 100 ng/g gentamicin limit applied to the fresh kidney of the 
recently slaughtered bovine (Chiesa et al., 2006). This example highlights the utility of 
measuring excreta (e.g., urine) to better estimate concentrations of drug in tissue (e.g., 
kidney). 
The challenge of excreta being a surrogate model to assess concentrations of drug and 
metabolites in human tissues is the limited understanding of how concentrations of drug 
and metabolites in the excreta will relate to the concentrations in the respective tissue. This 
challenge can be minimized by establishing a relationship between the concentration of 
drug and metabolites for excreta and tissues in animals (as illustrated by the above example 
with gentamicin in beef steers). In addition, translating that relationship from animal to 
human with in silico tools (e.g., PBPK modelling) and in vitro and in vivo human models 
(e.g., primary in vitro human cell models and humanized mice) will increase the confidence 
in including safety margins from exposure of drug and its metabolites in the tissues (in 
addition to plasma) where organ specific toxicity is observed. Below is a case example 
where the utility of semen as a surrogate model to assess the concentrations of drug and 
metabolites in dog testes was investigated.  
5.1.1 Case example: Utility of semen as a potential matrix to estimate drug and 
metabolites in testes 
In this case example, the potential of semen was evaluated as a matrix to determine the 
concentration of Drug A (same drug candidate described in the section for Toxicokinetics 
and Testicular Toxicity) and its metabolite (M1) in dog testes (for potential extrapolation to 
human). For this study, dogs were given a single oral dose of Drug A and then at different 
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time points dogs were ejaculated to collect semen and their testes were sampled. The 
toxicokinetic profile of M1 in semen and testes was similar (Table 7). Furthermore, the 
exposure of parent in testes also approximated the exposure of parent in semen where the 
exposure of Drug A in semen was approximately 2.5-fold higher than the exposure in testes 
(Table 7). These results suggest that semen approximated the exposure of Drug A and M1 in 
testes. Therefore, excreta may be a possible surrogate matrix to estimate tissue 
concentrations of drug candidate and its metabolites; however, supplementary systems like 
primary in vitro human cell models and humanized mice, combined with PBPK modelling, 
will be needed to extrapolate these results to human. 
 
  Half Life
(hr) 
Tmax 
(hr) 
Cmax 
(ng/mL or g)
AUClast 
(ng*hr/mL or g)
AUCinf 
(ng*hr/mL or g) 
Testes M1 13 7 2890 80787 81831 
Testes M2 3 1 28 87 108 
Testes Parent 18 7 12000 232701 233251 
Semen M1 16 7 3680 75766 75867 
Semen M2 ND ND ND ND ND 
Semen Parent 5 4 42700 593334 593391 
Table 7. Toxicokinetic Profile of Drug A and its Metabolites in Dog Testes and Semen. 
Before dosing, Beagle dogs (n=9) were trained for ejaculation 2 times/week. Dogs were 
administered a single oral dose of 15 mg/kg Drug A. Testes (n = 1/time point) were 
collected at 1, 4, 7, 24, 48, 72, 96, 168, and 336 hours post dose from dogs at each time point. 
Semen was also collected in the period between dosing and sacrifice. Bioanalysis of semen 
and testes for Drug A and its metabolites, M1 and M2, was performed. Toxicokinetic 
parameters were then determined.  
5.2 Utility of PBPK to estimate drug and metabolites in tissues 
PBPK models aid in the understanding of the disposition of chemicals in the body in 
different animal species, including humans. In toxicological research, PBPK modelling was 
initiated approximately 30 years or so, and mainly from an environmental toxicology 
perspective. For example, PBPK models were developed for polychlorinated biphenyls, 
methylene chloride, and other persistent lipophilic compounds starting in the mid 1980s 
(Andersen, 1995). In the past, the utilization of PBPK models in safety assessment 
departments within the pharmaceutical industry was not common, although the utilization 
of PBPK models is gaining momentum.  
The utility of PBPK models is to extrapolate from one environment to another; for example, 
PBPK models extrapolate from high to low dose, different routes of administration, 
interspecies, and different durations of exposure. All of these extrapolations are potentially 
needed to bridge knowledge of drug and metabolites concentrations in the tissues of safety 
assessment species (e.g., rat, dog, and monkey) to human tissues (Thompson et al., 2007). 
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For the best extrapolation, the mechanism of interaction leading to toxicity would be known; 
for example, a known biological process that is disturbed by a known entity, parent, and/or 
metabolite (Andersen, 1995). However in many cases, this mechanism is not known and 
PBPK models can assist in possibly identifying these mechanisms. Especially when 
modelling efforts address the appropriate questions, the systematic discovery of these 
mechanisms is possible. The key is to develop models with appropriate measures of tissue 
concentrations in animals and possibly excreta concentrations in animals and humans. To 
strengthen this extrapolation, in vitro systems, such as primary in vitro human cell models 
(e.g., hepatocyte sandwich-cultured cell model and proximal tubule cell monolayers), and 
humanized mice, will also provide vital parameters (e.g., pharmacokinetics rate constants)  
for the PBPK modelling in order to extrapolate tissues concentrations from animal to 
human. In 2001, a consensus building workshop sponsored by the Society of Toxicology 
concluded that the human in vitro systems, through quantitative measurements and PBPK 
modelling, can play an important role in dose-response assessment (MacGregor et al., 2001). 
Therefore in the near future, the combination of these technologies may allow researchers 
the ability to estimate drug and metabolites concentrations in human tissues. 
5.3 Utility of supplementary human models to estimate drug and metabolites in 
tissues 
The primary challenge in calculating safety margins in tissues where organ-specific toxicity is 
observed is the access to human tissue samples for the measurement of drug and its 
metabolites. One method to address this challenge is to simulate the distribution of drug and 
its metabolites in a human in vitro model. For example, development of valid and reliable 
techniques to quantify biliary excretion of drugs in healthy human volunteers is difficult. 
Measurements of drug concentrations in bile can only be obtained from patients diagnosed 
with diseases of the gallbladder and biliary tract who require medical procedures that allow 
this measurement (Ghibellini et al., 2006). However, there is a promising, recent technique to 
estimate bile in healthy human volunteers with an oroenteric catheter to aspirate duodenal 
secretions, and gamma scintigraphy to determine gallbladder contraction. This technique 
allowed the comparison of the biliary clearance of three compounds estimated with sandwich-
cultured human hepatocytes (a human in vitro model). The rank order of biliary clearance 
predicted from in vitro corresponded well with the in vivo biliary clearance values in 
mL/min/kg for Tc-99m mebrofenin (7.44 vs 16.1), Tc-99m sestamibi (1.20 vs 5.51), and Tc-99m 
piperacillin (0.028 vs 0.032) (Ghibellini et al., 2007). Since sandwich-cultured human 
hepatocytes need to uptake drug across their sinusoidal membrane in order to excrete the drug 
across their canalicular membrane for the in vitro measurement of biliary excretion, this 
verification of a good prediction of this human in vitro model from the clinical study suggests 
that the intracellular concentration within these sandwich-cultured human hepatocytes can 
also estimate concentrations of drug in the human hepatocyte in vivo. Therefore, in vitro 
models have the potential to supplement costly and difficult sampling in healthy human 
volunteers to estimate drug and metabolite concentrations in tissues and excreta. However, 
significantly more research is needed to realize this potential in existing models and to expand 
the amount of models for in vitro human tissue models. 
Another possible human model to estimate drug and metabolites in organs and/or tissues is 
mice with humanized organs and/or tissues. To create this model, a severe combined 
immunodeficient (SCID) mouse line is injected with human cells from the human tissue into 
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the respective mouse tissue. For example, injection of cryopreserved human hepatocytes 
through a small, left flank incision into the inferior splenic pole in a SCID mouse created a 
mouse with humanized liver that was replaced by more than 80% of human hepatocytes 
(Okumura et al., 2007). In this chimeric mice model, cefmetazole (CMZ) excretions in urine 
and feces were 81.0 and 5.9% of the dose, respectively; however, excretions in urine and 
feces in control SCID mice were 23.7 and 59.4% of the dose, respectively (Okumura et al., 
2007). Because CMZ is mainly excreted in urine in humans, the excretory profile in chimeric 
mice was demonstrated to be similar to humans. Interestingly in the chimeric mice, the 
hepatic mRNA expression of human drug transporters (e.g., MDR1, BSEP, MRP2, BCRP, 
OCT1, and OATP1B1/1B3) were detectable; whereas, the hepatic mRNA expression of 
mouse drug transporters in the chimeric mice was significantly lower than in the control 
SCID mice (Okumura et al., 2007). In conclusion, chimeric mice exhibited a humanized 
profile of drug excretion, suggesting that this chimeric mouse line would be a useful animal 
model to predict human ADME. Most studies have focused on humanized liver models; 
however, the potential for humanization of other organs and/or tissues in the mouse is 
evident in the near future. These new potential models will markedly improve the ability to 
estimate drug and metabolite concentrations in human organs and/or tissues. 
6. Conclusion  
For the determination of a safety margin, drug and metabolites concentrations are sampled 
in plasma, which is the most practical and widely accepted way of assessing this risk. 
However, most safety issues are not observed in the plasma but in the organs and/or 
tissues. Assumptions about concentrations of drug and metabolites in tissues from 
extrapolation with plasma may result in an inaccurate assessment of target organ exposure 
to drug and metabolites. Therefore, plasma is sometimes not a good surrogate for tissue 
levels of drug and its metabolites, especially for the assessment of risk for some types of 
organ-specific toxicity.  
Knowledge of toxicokinetics of an organ-specific toxicity can potentially assist in identifying 
a backup drug candidate that has a markedly lower potential for this organ-specific toxicity. 
Therefore, a hypothetical plan may be generated where focusing on tissue burden of the 
drug and its metabolites may actually ensure that a backup does not produce the same 
toxicity. For example, identifying a backup drug candidate with limited tissue distribution 
to the tissue where organ-specific toxicity was observed (e.g., testicular toxicity) markedly 
reduced the potential of these backups to cause these toxicities; furthermore, development 
of a backup drug candidate that is a substrate for efflux transporters which limit its 
distribution to the CNS (e.g., Pgp) can reduce the potential for this backup to cause CNS 
toxicity.  
In the future, innovative models such as 1) noninvasive in vivo measurements such as 
sampling excreta (e.g., urine, feces, bile, and semen), 2) in vitro systems, such as primary 
in vitro human cell models (hepatocyte sandwich-cultured model), 3) humanized mice, 
and 4) PBPK models, will provide more insight into the concentration of drug and 
metabolites in human organs and/or tissues. Therefore, these innovations will provide a 
more thorough risk assessment of safety which will include safety margins from exposure 
of drug and its metabolites in the tissues (in addition to plasma) where organ specific 
toxicity is observed.  
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